CD274 and non-small cell lung carcinoma: In the phase II CITYSCAPE trial, the TIGIT antibody tiragolumab combined with PD-L1 antibody atezolizumab for the treatment of PD-L1high NSCLC patients showed a significant benefit with an objective response rate of 66% compared to 24% with atezolizumab alone [107].